GlassScriptPhysician profile
Meagan White Smith
NPI 1790211894
$3,446.85
in general payments reported to CMS, 2019-2025
30 companies · $959 in 2025
The $959 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $141 · 2021: $726 · 2022: $363 · 2023: $467 · 2024: $791 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.38 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $628.28 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $440.89 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $122.87 | 2021-2023 | |
| Welch Allyn | $107.56 | 2021 | |
| Glaxosmithkline, LLC. | $106.53 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Hologic Sales and Service, LLC | $100.43 | 2021-2025 | Aptima |
| Lilly USA, LLC | $90.34 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Nestle Healthcare Nutrition INC. | $82.71 | 2021-2022 | |
| Corcept Therapeutics | $68.48 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $65.50 | 2020-2021 | |
| Exact Sciences Corporation | $65.48 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.66 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $35.08 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.41 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $30.47 | 2021 | |
| Myriad Genetic Laboratories, INC. | $24.84 | 2024 | Myrisk |
| Astellas Pharma US INC | $24.18 | 2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $24.02 | 2021 | |
| Redhill Biopharma INC. | $23.96 | 2021 | |
| Allergan, INC. | $23.37 | 2020 | |
| Lundbeck LLC | $18.88 | 2023 | Rexulti |
| Baxter Healthcare | $16.69 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Amarin Pharma, INC. | $15.98 | 2021 | |
| Amgen INC. | $15.87 | 2023 | Otezla, Repatha |
| Dexcom, INC. | $15.86 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.52 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $15.25 | 2021 | |
| Almatica Pharma LLC | $12.80 | 2021 | |
| Currax Pharmaceuticals LLC | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.